VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

Core Insights - VivoSim Labs, Inc. announced the successful presentation of its NAMkind™ platform for liver toxicology prediction at the Digestive Disease Week Conference, showcasing its leading predictive capabilities in the industry [1][2] Company Overview - VivoSim's NAMkind™ liver model achieved a sensitivity of 87.5% in identifying liver-toxic drugs, with a specificity of 100%, indicating no false positives among non-toxic compounds [2] - The platform utilizes a physical organoid wet lab model made from human donor cells and is developing advanced in silico predictions using AI trained on proprietary data [3] Market Context - The FDA's initiative to phase out animal testing in favor of non-animal methods is expected to significantly boost the adoption of VivoSim's NAM models, which could disrupt a market exceeding $10 billion [4][7] - VivoSim aims to reduce clinical trial failures and associated costs by 50% through improved predictions of liver toxicity, addressing a critical issue in drug development [5] Product Capabilities - The NAMkind™ intestine models are designed to provide insights on endpoints currently unavailable to researchers, potentially improving patient outcomes during chemotherapy [6] - The company is positioned to fill the gap in commercially available solutions as the FDA moves towards NAM models, leveraging AI and human organ models for safer and more efficient drug development [7]